greeksoup/ stock research
Stock research / United States / SLN / Filings

Silence Therapeutics plc SEC filings

Silence Therapeutics filed 24 documents with the SEC in the last twelve months, the latest report being the 10-Q of 10 August 2026. The latest filing, on 19 October 2026, was a DEFA14A: defa14a.

Filings in twelve months2415 of them 8-K news
Latest report10-Qfiled 10 Aug 2026
Latest filingDEFA14A19 Oct 2026
Last results, two-day move+23.2%results filed 10 Aug 2026
New to this? How to read this page
  1. Companies file with the SEC when something happens. 10-Q and 10-K are the quarterly and annual reports; 8-K is news that cannot wait for the next report.
  2. An 8-K says which items it covers, such as results, a change at the top or a big contract. A foreign company files a 6-K instead.
  3. The results release is usually an 8-K filed the day results come out, before the 10-Q or 10-K.
  4. Every filing links to the original on EDGAR, the SEC's own site.

Twelve months of filings

by kind

Most of the filings were other company news (11). Results came out 4 times.

Each mark is one filing on the day it was filed, in rows by kind. Hover or tap a mark for the form and what it was about.

The share price around each results release

close before to close after

Over the last 4 releases the share price moved 10.4% on average in the two days around results, the most on 10 Aug 2026 (+23.2%).

6 Nov 2025+5.4%$6.24 to $6.58
5 Mar 2026+7.8%$5.78 to $6.23
7 May 2026-5.3%$7.36 to $6.97
10 Aug 2026+23.2%$11.95 to $14.72
Daily closeResults filed

Each ring marks a results filing. The move runs from the last close before the filing to the first close after it, so it covers results released before the open or after the close. Hover the line for any day's close.

What the company told investors on 8-K

15 filings

Silence Therapeutics's 15 news filings (8-K) were mostly about regulation FD disclosure (5) and other events (4).

  • Regulation FD disclosureMaterial shared with investors, often slides or a presentation
    5 · latest 19 Oct 2026
  • Other eventsNews the company chose to file
    4 · latest 12 Aug 2026
  • Results of operationsThe quarterly results release
    4 · latest 10 Aug 2026
  • Officer or director changeSomeone joined, left or changed role at the top
    4 · latest 16 Jul 2026
  • Material agreementA large contract or deal was signed
    3 · latest 19 Oct 2026
  • Shareholder voteResults of a vote at a shareholder meeting
    1 · latest 16 Jun 2026
  • Termination of a material agreementA large contract ended
    1 · latest 18 May 2026

Each line is one kind of news, with what it means in plain words. Each square is one filing; a filing can carry more than one kind, so the squares can add up to more than the filings. The date opens the latest one on EDGAR.

How it compares

every company on the site

    The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.

    Every filing as a table

    In the last twelve months Silence Therapeutics plc filed 24 documents with the SEC of the kinds listed here: 15 current reports (8-K), about 5 regulation FD disclosure; 4 other events; 4 results of operations; 4 officer or director change; 3 material agreement; 3 quarterly reports (10-Q), 2 additional proxy materials (DEFA14A), 1 annual report to shareholders (ARS), 1 proxy statement (DEF 14A), 1 employee share plan registration (S-8), 1 annual report (10-K). The latest, filed 19 October 2026: DEFA14A, additional proxy material. The 10-K, the 10-Qs and the proxy statement themselves, each with a link to open it, are on the documents page.

    FiledFormWhat it was aboutPeriod or event dateFiling
    19 October 2026DEFA14Aadditional proxy materialEDGAR
    19 October 2026DEFA14Aadditional proxy materialEDGAR
    19 October 20268-KMaterial agreement, Regulation FD disclosure18 October 2026EDGAR
    12 August 20268-KMaterial agreement, Other events10 August 2026EDGAR
    10 August 20268-KRegulation FD disclosure, Other events10 August 2026EDGAR
    10 August 202610-Qquarterly report30 June 2026EDGAR
    10 August 20268-KResults of operations10 August 2026EDGAR
    16 July 20268-K/AOfficer or director change10 July 2026EDGAR
    23 June 20268-KRegulation FD disclosure23 June 2026EDGAR
    16 June 20268-KShareholder vote16 June 2026EDGAR
    11 June 20268-KOther events11 June 2026EDGAR
    18 May 20268-KMaterial agreement, Termination of a material agreement, Other events18 May 2026EDGAR
    7 May 202610-Qquarterly report31 March 2026EDGAR
    7 May 20268-KResults of operations7 May 2026EDGAR
    29 April 2026ARSannual report to shareholders31 December 2025EDGAR
    29 April 2026DEF 14Aproxy statement16 June 2026EDGAR
    5 March 2026S-8employee share plan registrationEDGAR
    5 March 202610-Kannual report31 December 2025EDGAR
    5 March 20268-KResults of operations, Regulation FD disclosure5 March 2026EDGAR
    22 December 20258-K/AOfficer or director change14 December 2025EDGAR
    22 December 20258-KOfficer or director change18 December 2025EDGAR
    15 December 20258-KOfficer or director change, Regulation FD disclosure14 December 2025EDGAR
    6 November 202510-Qquarterly report30 September 2025EDGAR
    6 November 20258-KResults of operations6 November 2025EDGAR
    An 8-K is what a company files within four business days of a material event; the SEC numbers the events, and the words here are the SEC's own headings, shortened.
    Read moreForm 4, Form 144, 13F and Schedule 13D and 13G have their own pages. Prospectus supplements and correspondence are not listed.